已发表论文

Pristimerin 通过 miR-542-5p/EGFR 轴抑制滋养层细胞上皮-间质转化

 

Authors Shu C, Yu X, Cheng S, Jing J, Hu C, Pang B

Received 4 August 2020

Accepted for publication 18 October 2020

Published 2 November 2020 Volume 2020:14 Pages 4659—4670

DOI https://doi.org/10.2147/DDDT.S274595

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Jianbo Sun

Background: Ectopic pregnancy (EP) is an ectopic embryo implantation occurred outside the uterine cavity. Nowadays, more attention have garnered in fast and effective treatment with less side effects. Pristimerin is known as the clinical application for anti-cancer, and the effect on EP therapy is still unclear.
Materials and Methods: Trophoblast cell line HTR-8/SVneo was used; then, we performed cell counting kit-8 assay, wound healing assay, flow cytometry and real-time polymerase chain reaction analysis (RT-PCR) to detect the cell viability, migration ability, apoptosis and epithelial–mesenchymal transition (EMT) under pristimerin treatment. In addition, public bioinformatic database was used to discover the connection between molecular and genes. Finally, we used miRNA transfection and RT-PCR techniques to determine the underlying molecular mechanism.
Results: We revealed that pristimerin inhibited trophoblast cells proliferation, migration and EMT, while induced trophoblast cell apoptosis. Furthermore, expression of miR-542-5p, AGO2 and EGFR was suppressed in HTR-8/SVneo cells post pristimerin treatment, and miR-542-5p silence showed the same effect. Combing pristimerin treatment and miR-542-5p silence showed a synergistic action.
Conclusion: Pristimerin could be an effective treatment to block embryo implantation by miR-542-5p and EGFR down-regulation.
Keywords: pristimerin, trophoblast cell, unruptured ectopic pregnancy, miR-542-5p, EGFR